This systematic review was designed to provide more precise effect estimates of inhibitor
development for the various types of F8 gene mutations in patients with severe hemophilia …

This paper emphasizes the importance of distinguishing between the prevalence, incidence
and cumulative incidence of inhibitors in haemophilia A. Incidence and cumulative …

Background For previously untreated children with severe hemophilia A, it is unclear
whether the type of factor VIII product administered and switching among products are …

The objective of this study was to examine the association of the intensity of treatment,
ranging from high-dose intensive factor VIII (FVIII) treatment to prophylactic treatment, with …

Abstract The CANAL Study (Concerted Action on Neutralizing Antibodies in severe
hemophilia A) was designed to describe the relationship between treatment characteristics …

Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is
effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII …

This review focuses on selected areas that should interest both the scientist and the clinician
alike: polymorphisms within the factor VIII and factor IX genes, their linkage, and their ethnic …

The formation of alloantibodies against factor VIII (FVIII) or factor IX (FIX) is the most severe
complication of replacement therapy in patients with haemophilia. In the last decade, genetic …

Six recombinant factor VIII (rFVIII) products have been marketed worldwide. In 2013, the
Research of Determinants of Inhibitor Development (RODIN) study group reported an …

It has been suggested that plasma-derived factor VIII products induce fewer inhibitors than
recombinant factor VIII products. We investigated the relationship of factor VIII product type …